The global market for validation, calibration, and standardization in life sciences is expected to grow from $2.7 billion in 2024 to $3.9 billion by 2030, at a CAGR of 6.7%. Growth is fueled by stricter regulatory demands, the rise of complex biologics and advanced therapies, and digital transformation in manufacturing processes. North America leads the market due to strong FDA regulations and early tech adoption. The shift to AI, IoT, and cloud-based systems is reshaping quality assurance, creating opportunities for technology providers in this essential, regulation-driven sector.
IBM's business model remains strong despite a 7% decline in mainframe infrastructure revenue, supported by loyal legacy customers and solid free cash flow. Software growth, especially an 11% increase in Red Hat revenue, helps offset mainframe challen...
Energy prices cooled in June, easing inflation pressures despite ongoing tensions between the U.S. and Iran near the Strait of Hormuz. Morgan Stanley reported record quarterly revenue and profit, boosted by a surge in equities trading fueled by the A...
IBM reported earnings and revenue below expectations due to enterprises reducing spending on traditional IT systems to invest in their own AI infrastructure. This shift indicates companies prefer developing on-premises AI solutions with cheaper open-...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
IBM introduced Power Autonomous Operations, an AI agent that autonomously monitors and resolves issues in Power systems up to 15 times faster than manual methods, enhancing system uptime and efficiency. Alongside, IBM launched the Power S1112, a comp...
